Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

(2020) Chih-Cheng Lai et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Novel Coronavirus Originating in Wuhan, China

(2020) Alexandra L. Phelan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Drug–Drug Interactions with Direct Oral Anticoagulants

(2020) Kathrin I. Foerster et al.   CLINICAL PHARMACOKINETICS

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

(2020) Christian A. Devaux et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants

(2019) Sophie Testa et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2018) Jan Steffel et al.   EUROPEAN HEART JOURNAL

Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants

(2018) S. Testa et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

(2018) Robert Gosselin et al.   THROMBOSIS AND HAEMOSTASIS

Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics

(2016) Sophie Testa et al.   THROMBOSIS RESEARCH

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

(2013) Wolfgang Mueck et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban

(2013) Inna Y. Gong et al.   CANADIAN JOURNAL OF CARDIOLOGY

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

(2013) Paul A. Reilly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Oral Anticoagulant Therapy

(2012) Walter Ageno et al.   CHEST

Evidence-Based Management of Anticoagulant Therapy

(2012) Anne Holbrook et al.   CHEST